UConn Health Professor of Medicine Daniel Rosenberg, PhD is partnering with CaroGen Corporation to use science and technology along with patient input to develop a vaccine against colorectal cancer.

CaroGen Corporation is an emerging vaccine company with R&D facilities at UConn’s Technology Incubation Program (TIP) in Farmington. The company’s novel and transformative platform technology is based on replication-proficient virus-like vesicles for the treatment of infectious diseases and cancer, in particular chronic hepatitis B virus infection.